PharmaResearch Co Ltd
KOSDAQ:214450
PharmaResearch Co Ltd
Short-Term Debt
PharmaResearch Co Ltd
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Short-Term Debt
₩250m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Short-Term Debt
₩2T
|
CAGR 3-Years
57%
|
CAGR 5-Years
46%
|
CAGR 10-Years
22%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Short-Term Debt
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Short-Term Debt
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
NatureCell Co Ltd
KOSDAQ:007390
|
Short-Term Debt
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Short-Term Debt
₩5B
|
CAGR 3-Years
30%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
PharmaResearch Co Ltd
Glance View
In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.
See Also
What is PharmaResearch Co Ltd's Short-Term Debt?
Short-Term Debt
250m
KRW
Based on the financial report for Dec 31, 2024, PharmaResearch Co Ltd's Short-Term Debt amounts to 250m KRW.
What is PharmaResearch Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 3Y
-75%
Over the last year, the Short-Term Debt growth was -38%. The average annual Short-Term Debt growth rates for PharmaResearch Co Ltd have been -75% over the past three years .
You don't have any saved screeners yet